StockData
MediciNova Inc logo

MediciNova Inc (MNOV) company profile

MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.34+0.00 (0.00%)

Close on Nov 17, 2026Market cap $65.96MP/E –Yield –

About MediciNova

Pharmaceutical Preparations, SIC 2834

MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious medical conditions with unmet needs, primarily targeting the United States commercial market. Its research and development efforts center on two principal product candidates: MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is an oral anti-inflammatory and neuroprotective agent being investigated for neurological and respiratory indications, including progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, and the prevention of acute respiratory distress syndrome. MN-001 is evaluated for fibrotic and metabolic conditions, including nonalcoholic fatty liver disease and hypertriglyceridemia. The company engages with trial participants and works alongside research institutions, government entities, and corporate partners.

The company conducts clinical trials, research collaborations, and lease operations across the United States, Canada, the United Kingdom, and Japan. MediciNova maintains its principal executive headquarters in La Jolla, California.

Summary of the business section of MediciNova's latest annual report, written by StockData.

Company profile

Company

Legal name
MediciNova Inc
Headquarters
La Jolla, CA
Address
4275 Executive Square, Suite 300 92037
Phone
(858) 373-1500
Employees
6, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
MNOV
Exchange
Nasdaq
IPO date
Dec 8, 2006
Shares outstanding
49M, Aug 11, 2026
Public float
$62.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1226616
CUSIP
58468P206
ISIN
US58468P2065
FIGI
BBG000RDP030
Share class FIGI
BBG001SNG8P4
EIN
33-0927979

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yuichi IwakiPresident and CEO1,091,933
Kazuko MatsudaChief Medical Officer322,996
Hideki NagaoDirector0
Carolyn BeaverDirector–
Nicole LemerondDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.76M$1.34M$735.62K$64–
FY2024$1.41M$1.61M$424.60K$102–
FY2023$1.39M$1.15M$846.68K$73–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Yuichi Iwaki, M.D., Ph.D.
President and Chief Executive Officer
$657.38K$729.65K$328.69K$21.00K$1.74M+23%
Kazuko Matsuda, M.D., Ph.D., MPH
Senior Vice President, Chief Medical Officer
$514.42K$589.89K$205.77K$21.00K$1.33M+33%
David H. Crean, Ph.D.
Chief Business Officer
$120.00K–––$120.00K+21%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“We have six employees as of the date of this report, all of which are full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?